Journey Medical Corp
NASDAQ:DERM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.98
9.26
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Journey Medical Corp
Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.
Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.
Revenue Growth: Journey Medical reported third quarter 2025 revenue of $17.6 million, up 21% year-over-year, driven largely by the successful launch of Emrosi.
Emrosi Launch: Emrosi contributed $4.9 million in Q3 revenue, up 75% from Q2, with prescriptions more than doubling to 18,198 in the quarter.
Margin Expansion: Gross margin improved sequentially throughout 2025, reaching 67.4% in Q3, aided by higher-margin products and lower inventory costs.
Reduced Loss: Net loss narrowed to $2.3 million, or $0.09 per share, compared to $2.4 million in the same quarter last year.
EBITDA Outlook: Management expects the company to become sustainably EBITDA positive in the fourth quarter of 2025.
Payer Access Progress: Contracts with 2 of the 3 major GPOs for Emrosi are secured, with the third expected in early 2026; broader coverage is anticipated to reduce reliance on co-pay assistance.
Operating Leverage: Operating expenses rose just 9% year-over-year, supporting growing operating leverage as sales ramp.
Stable Legacy Products: Qbrexza, Accutane, AMZEEQ, and ZILXI revenues were flat sequentially; Accutane is considered stable despite generic competition.
